Tonix Pharmaceuticals Surpasses EPS Expectations in Q1 2025 Amid Revenue Shortfall
Tonix Pharmaceuticals reported Q1 2025 financial results, with a GAAP EPS of -$2.84 and revenue of $2.43 million, despite surpassing earnings expectations.
- Tonix Pharmaceuticals Holding Corp
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read